Prescription Digital Therapeutics for Insomnia
Episode 74, Oct 07, 2022, 10:00 AM
Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with Yuri Maricich, MD, MBA, internal medicine physician, and chief medical officer and head of development, Pear Therapeutics. He joined the show to discuss the current use of digital therapeutics in insomnia such as cognitive behavioral therapy, the state of education and treatment for the sleep disorder, some of the challenges in care, and more.
Episode Breakdown:
In this episode, we spoke with Yuri Maricich, MD, MBA, internal medicine physician, and chief medical officer and head of development, Pear Therapeutics. He joined the show to discuss the current use of digital therapeutics in insomnia such as cognitive behavioral therapy, the state of education and treatment for the sleep disorder, some of the challenges in care, and more.
Episode Breakdown:
- 1:15 – The positives of digital therapeutics in insomnia care
- 3:50 – Overview of a recent study from Maricich and colleagues
- 8:40 – Prioritization of sleep in clinical care
- 11:20 – Lack of clinical use of prescription digital therapeutics
- 13:05 – Neurology News Minute
- 15:30 – Differences for CBT-I among treatment-naïve individuals
- 18:05 – Use of CBT-I as a supplementary treatment tool
- 20:10 – Research needs and ongoing efforts
- 23:15 – What clinicians need to know about CBT-I and digital therapeutics
- 25:50 – Closing thoughts
This episode is brought to you by the Medical World News streaming service. Check out new content and shows every day, only at medicalworldnews.com
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
- Alzheimer Disease Agent Lecanemab Shows Reduction in CDR-Sum of Boxes in Clarity AD
- Verdiperstat Fails to Differentiate From Placebo in Critical HEALEY ALS Platform Trial
- AMX0035 Approved for the Treatment of ALS
- CNM-Au8 Shows Survival Benefit in HEALEY ALS Trial, But Fails to Meet End Points
Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
REFERENCES
1. Forma F, Knight TG, Thorndike FP, et al. Real-World Evaluation of Clinical Response and Long-Term Healthcare Resource Utilization Patterns Following Treatment with a Digital Therapeutic for Chronic Insomnia. Clinicoecon Outcomes Res. 2022;14:537-546. doi:10.2147/CEOR.S368780